Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy and Safety of Oxymorphone Immediate Release in Post-surgical Acute Pain

This study has been completed.
Sponsor:
Information provided by:
Endo Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00226395
First received: September 23, 2005
Last updated: February 12, 2010
Last verified: February 2010

September 23, 2005
February 12, 2010
September 2004
Not Provided
Time to discontinuation due to all causes
Same as current
Complete list of historical versions of study NCT00226395 on ClinicalTrials.gov Archive Site
  • The following are the secondary endpoints during the initial 6 hours following the first dose of study medication:
  • - 6-Hour Sum of Pain Intensity Differences (SPID; VAS and categorical)
  • - 6-Hour Total Pain Relief Scores (TOTPAR; VAS and categorical)
  • - Time (in hours) to First Perceptible Pain Relief
  • - Time (in hours) to Meaningful Pain Relief
  • - Hourly Pain Relief Scores
  • - Hourly Pain Intensity Difference Scores
  • The following are the secondary endpoints during the multiple dosing phase:
  • - Mean average pain intensity scores collected during the dosing intervals.
  • - Mean current pain intensity (VAS) collected during the dosing intervals.
  • - Patient's global evaluation of study medication at the end of study.
  • - Physician's global evaluation of study medication at the end of study.
  • The following are the secondary endpoints during the initial 6 hours following the first dose of study medication:
  • - 6-Hour Sum of Pain Intensity Differences (SPID; VAS and categorical)
  • - 6-Hour Total Pain Relief Scores (TOTPAR; VAS and categorical)
  • - Time (in hours) to First Perceptible Pain Relief
  • - Time (in hours) to Meaningful Pain Relief
  • - Hourly Pain Relief Scores
  • - Hourly Pain Intensity Difference Scores
  • The following are the secondary endpoints during the multiple dosing phase:
  • - Mean average pain intensity scores collected during the dosing intervals.
  • - Mean current pain intensity (VAS) collected during the dosing intervals.
  • - Patient’s global evaluation of study medication at the end of study.
  • - Physician’s global evaluation of study medication at the end of study.
Not Provided
Not Provided
 
Efficacy and Safety of Oxymorphone Immediate Release in Post-surgical Acute Pain
Randomized, Double-Blind, Placebo- and Active-Control, Single- and Multiple-Dose Evaluation of the Analgesic Efficacy and Safety of Oxymorphone Immediate Release (IR) Tablets in Patients With Moderate/Severe Pain Following Abdominal Surgery

The purpose of this study is to evaluate the analgesic efficacy and safety of two doses of oxymorphone immediate release (IR) compared to placebo and oxycodone in post-surgical pain.

Following abdominal surgery and after sufficient washout from post-surgical analgesia, patients were randomized to one of the following four treatment groups; 1) oxymorphone IR 10 mg, 2) oxymorphone IR 20 mg, 3) oxycodone IR 15 mg, or 4) placebo. Total duration of treatment was 48 hours. Patients were required to take the study medication every 4-6 hours. After the first dose, periodic pain assessments were performed for the first six hours. Subsequently, patients were required to assess their current pain intensity and average pain intensity since the last dose of study medication just prior to every dose.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Acute Pain
Drug: Oxymorphone immediate release
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
320
August 2005
Not Provided

Inclusion Criteria:

  • Male or female patients 18 years of age or older
  • Patients undergoing surgery through an abdominal incision of at least 3 cm who are expected to be hospitalized for at least 36 hours and are expected to subsequently require at least 48 hours of oral opioid therapy.
  • Washout of at least 45 minutes for parenteral and 4 hours for IM analgesia.
  • Initial pain intensity score of at least 50 mm on a 100-mm VAS and a categorical pain rating of moderate or severe on a scale of none, mild, moderate, or severe.
  • Written informed consent.

Exclusion Criteria:

  • Known allergy or significant reaction to opioids.
  • History of chronic opioid use or opioid abuse within 6 months prior to study entry.
  • History of alcohol or substance abuse within the last 3 years.
  • Have been a participant in a study of an investigational drug or device within 30 days prior to study entry.
  • Have been a previous participant in an oxymorphone clinical trial.
  • Are currently taking or have taken a monoamine oxidase inhibitor (MAOI) drug within 2 weeks prior to study entry.
  • Are currently taking or have taken St. John's Wort >1000 mg/day within 2 days prior to study entry.
  • Use of long-acting oral and parenteral analgesics (opioid, non-opioid or non-steroidal anti-inflammatory drug [NSAID]) within 12 hours (at least 24 hours for cyclooxygenase-2 [COX 2] analgesics) prior to receiving study medication.
  • Are not stabilized on the following medications for at least 4 weeks prior to dosing: tricyclic antidepressant drugs; serotonin reuptake inhibitors; amphetamines used for attention-deficit hyperactivity disorder (ADHD)
  • Have a history of seizure.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00226395
EN3203-009
Not Provided
Not Provided
Endo Pharmaceuticals
Not Provided
Not Provided
Endo Pharmaceuticals
February 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP